Evidence map›Paper›PMID 28362068›Full record

ArticleJournal of the International AIDS Society2017

Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

Anders Boyd, Julie Bottero, Patrick Miailhes, Caroline Lascoux-Combe, Hayette Rougier, Pierre-Marie Girard, Lawrence Serfaty, Karine Lacombe

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  3. Review
  4. Impact of Socio-Economic, Behavioural and Clinical Factors on Liver Disease Progression in Individuals With HIV and Hepatitis B.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Chronic hepatitis B and HIV coinfection.Topics in antiviral medicine · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Anders BoydINSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Julie BotteroService des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, AP-HP, Paris, France.
Patrick MiailhesService des Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Caroline Lascoux-CombeService des Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, AP-HP, Paris, France.
Hayette RougierInstitut de Médecine et d'Epidémiologie Appliquée, Paris, France.
Pierre-Marie GirardService des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, AP-HP, Paris, France.
Lawrence SerfatyService Hépato-gastro-entérologie, Hôpital Saint-Antoine, Paris, France.
Karine LacombeService des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, AP-HP, Paris, France.
Institut Pierre Louis d‘Épidémiologie et de Santé Publique · FRAssistance Publique – Hôpitaux de Paris · FRHôpital de la Croix-Rousse · FRHôpital Saint-Antoine · FRHôpital Saint-Louis · FRInstitut de Médecine et d'Epidémiologie Africaines · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong-term tenofovir disoproxil fumarate (TDF) use has been associated with significant regression of liver fibrosis during hepatitis B virus (HBV) mono-infection, yet little is known during HIV-HBV coinfection. The aim of this study was to evaluate the evolution of liver fibrosis and its determinants in TDF-treated coinfected patients.

methodsIn this prospective cohort study, 167 HIV-HBV-infected patients initiating TDF-containing antiretroviral therapy were included. Fibrosis was assessed using the FibroTest® at baseline and every six to twelve months. Risk factors for fibrosis progression (F0-F1-F2 to F3-F4) and regression (F3-F4 to F0-F1-F2) were evaluated.

resultsAt baseline, 134 (80.2%) patients had detectable HBV-DNA (median = 4.93 log

conclusionLiver fibrosis levels are stable for most coinfected patients undergoing TDF, despite control of HBV replication. Nevertheless, a concerning amount of liver fibrosis progression did occur, which could be partly explained by metabolic abnormalities and past severe immunosuppression and requires further evaluation.

Indexed as

AdultAnti-HIV AgentsCoinfectionDisease ProgressionFemaleFranceHepatitis BHepatitis B e AntigensHepatitis B virusHIV InfectionsHumansLiver CirrhosisMaleMiddle AgedProspective StudiesTenofovirAnti-HIV AgentsHepatitis B e AntigensTenofovirhepatocellular carcinomaimmunosuppressionliver cirrhosisliver fibrosisnoninvasive markers

Identifiers

PMID28362068
PMCPMC5467614
OpenAlexW2592630671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.